Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

66.69 

-0.35 -0.5%

as of May 17 '21

52 Week Range:

16.40 92.00


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Mar '19 Dec '19 Mar '20 Dec '20
Equity (BVPS) 6.06
4.15
6.04
5.49
4.98
growth rate -31.5% 45.5% -4.7% -4.8%
Earnings BIT -5.23
-13.41
-32.16
-69.56
-90.87
-106.37
-136.58
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Avg.PE -11.68
-20.67
-20.67
-20.67
-20.67
growth rate 0.0% 0.0% 0.0% 0.0%
ROA -26.71
-16.60
-20.01
-23.59
-29.21
-26.56
growth rate 0.0% 0.0% 0.0% 0.0% 0.0%
ROE -42.40
-22.82
-26.46
-29.50
-36.34
-33.69
growth rate 0.0% 0.0% 0.0% 0.0% 0.0%
ROIC -42.40
-23.20
-27.25
-31.41
-36.39
-31.96
growth rate 0.0% 0.0% 0.0% 0.0% 0.0%
Cur. Ratio 7.26
9.15
11.32
8.01
8.12
9.60
growth rate 26.0% 23.7% -29.2% 0.7% 8.7%
Quick Ratio 7.18
9.10
11.20
7.93
7.98
9.33
growth rate 26.7% 23.1% -29.2% 0.3% 8.1%
Leverage 1.22
1.42
1.25
1.25
1.24
1.28
growth rate 16.4% -12.0% 0.0% -0.4% 1.6%
Balance Sheet Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Mar '19 Dec '19 Mar '20 Dec '20
Acct.Receivable 1.00
6.45
10.47
7.55
4.62
2.13
growth rate 545.4% 62.2% -27.9% -21.8% -32.1%
Acct.Payable 0.20
1.36
4.65
2.17
2.71
3.94
10.46
growth rate 583.4% 242.1% -53.3% 24.7% 20.6% 62.9%
Cur.Assets 10.13
77.63
281.31
354.83
324.98
3.59
289.48
269.76
616.52
growth rate 666.3% 262.4% 26.1% -8.4% -98.9% 7,961.3% -6.8% 128.5%
Total Assets 10.69
82.14
298.97
376.24
347.32
3.59
334.28
314.75
676.32
growth rate 668.1% 264.0% 25.8% -7.7% -99.0% 9,208.8% -5.8% 114.9%
Cash 9.85
75.82
273.06
340.68
58.86
57.23
160.02
growth rate 670.1% 260.2% 24.8% -82.7% -1.4% 67.2%
Cur.Liabilities 2.36
10.70
30.73
31.36
40.57
35.63
35.30
64.25
growth rate 354.1% 187.3% 2.1% 29.4% -6.3% -0.9% 82.0%
Liabilities 3.13
14.78
89.13
75.64
69.40
64.40
66.99
149.25
growth rate 372.6% 502.9% -15.1% -8.3% -3.7% 4.0% 122.8%
LT Debt 0.00 0.00
growth rate
Equity -8.88
-21.20
209.84
300.60
277.92
269.88
527.07
growth rate 0.0% 100.0% 43.3% -7.5% -1.5% 39.8%
Common Shares 0.61
18.00
22.00
36.00
43.00
47.00
50.60
56.00
growth rate 2,865.4% 22.2% 63.6% 19.4% 4.6% 7.7% 10.7%
Cash Flow Statement Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Mar '19 Dec '19 Mar '20 Dec '20
Capital Expenditures 0.41
2.55
6.17
10.09
6.36
6.79
3.59
growth rate 519.2% 141.4% 63.7% -37.0% 3.4% -27.4%
Cash Dividends 0.00 0.00
growth rate
Cash From OA -3.48
-1.76
36.11
-65.28
-61.26
-103.24
-49.91
growth rate 0.0% 100.0% -100.0% 0.0% 0.0% 0.0%
FCF per Share 1.15
-1.99
-1.94
-1.93
-0.82
growth rate -100.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock 0.52
170.77
170.77
142.98
growth rate 32,520.4% 0.0% -16.3%
FCF -3.90
-4.00
30.00
-75.00
-68.00
-110.00
-53.00
growth rate 0.0% 100.0% -100.0% 0.0% 0.0% 0.0%
Income Statement Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Mar '19 Dec '19 Mar '20 Dec '20
Sales 6.04
16.48
26.12
30.43
43.10
57.99
growth rate 172.7% 58.5% 16.5% 19.0% 16.0%
Op.Income -5.23
-13.41
-32.16
-69.56
-90.87
-106.37
-136.58
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
IBT -14.31
-13.41
-31.63
-67.54
-85.34
-99.53
-134.23
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Net Income -14.31
-12.40
-31.63
-67.54
-85.34
-99.53
-134.23
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
EPS -0.70
-1.42
-1.88
-1.98
-2.11
-2.40
growth rate 0.0% 0.0% 0.0% 0.0% 0.0%
Gross Profit -1.66
-5.13
-15.36
-41.53
-58.68
-65.31
-92.41
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
R&D 11.17
31.84
67.65
89.12
108.41
150.41
growth rate 185.1% 112.5% 31.7% 10.3% 17.8%

Quarterly Statements

Item Name Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Earnings BIT -33.05
-33.03
-28.10
-42.40
-46.43
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Acct.Receivable 13.37
3.86
1.22
2.13
0.95
growth rate -71.1% -68.5% 75.0% -55.3%
Acct.Payable 3.87
0.01
7.78
10.46
8.69
growth rate -99.8% 110,971.4% 34.5% -16.9%
Cur.Assets 269.76
446.37
416.25
616.52
601.08
growth rate 65.5% -6.8% 48.1% -2.5%
Total Assets 314.75
490.83
458.56
676.32
716.89
growth rate 55.9% -6.6% 47.5% 6.0%
Cash 80.99
361.69
179.75
160.02
145.28
growth rate 346.6% -50.3% -11.0% -9.2%
Cur.Liabilities 35.30
59.14
55.87
64.25
60.70
growth rate 67.5% -5.5% 15.0% -5.5%
Liabilities 66.99
139.24
128.94
149.25
growth rate 107.9% -7.4% 15.8%
LT Debt
growth rate
Equity 247.76
351.59
329.62
527.07
545.87
growth rate 41.9% -6.3% 59.9% 3.6%
Common Shares 0.01
0.01
0.01
0.01
0.01
growth rate 20.0% 0.0% 16.7% 0.0%
Cash Flow Statement Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Capital Expenditures 0.85
1.04
0.70
1.01
growth rate 22.6% -32.6% 44.1%
Cash Dividends
growth rate
Cash From OA -38.55
57.42
-28.56
-40.23
-52.38
growth rate 100.0% -100.0% 0.0% 0.0%
Sale Purchase of Stock
growth rate
FCF -39.39
56.38
-29.26
-41.23
growth rate 100.0% -100.0% 0.0%
Income Statement Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Sales 12.92
16.26
22.22
6.60
6.45
growth rate 25.9% 36.6% -70.3% -2.3%
Op.Income -33.05
-33.03
-28.10
-42.40
-46.43
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -31.81
-32.39
-27.84
-42.19
-46.21
growth rate 0.0% 0.0% 0.0% 0.0%
Net Income -31.81
-32.39
-27.84
-42.19
-46.21
growth rate 0.0% 0.0% 0.0% 0.0%
Gross Profit -21.73
-21.51
-17.54
-31.64
growth rate 0.0% 0.0% 0.0%
R&D 34.65
37.77
39.76
38.23
39.28
growth rate 9.0% 5.3% -3.8% 2.7%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

E (19.26)

YOY Growth Grade:

F (12.06)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -20.67 -33.35 -21.56
EPS / Growth 0.0% -2.00 30.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 26.7% 31.1%
Future PE 0.00 0.01 20.73
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.